SDH-Deficient Gastrointestinal Stromal Tumor (GIST) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

SDH-Deficient Gastrointestinal Stromal Tumor (GIST) Market Outlook

Thelansis’s “SDH-Deficient Gastrointestinal Stromal Tumor (GIST) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential SDH-Deficient Gastrointestinal Stromal Tumor (GIST) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

SDH-Deficient Gastrointestinal Stromal Tumor (GIST) Overview

Gastrointestinal stromal tumors (GISTs) are the predominant mesenchymal tumors in the gastrointestinal tract. They primarily occur in the stomach (50%-60%) and small intestine (30%-35%), while their occurrence in the colon and rectum is less common (5%), and in the esophagus, it is rare (<1%). Additionally, GISTs can develop within the abdominal cavity, specifically in the omentum, mesentery, or retroperitoneum (occurring in less than 5% of all GISTs). Specific mutations in the KIT gene drive the majority of GISTs (75%-80%) or PDGFRA gene (10%). However, around 10%-15% of GISTs do not exhibit detectable mutations in KIT or PDGFRA and are called KIT/PDGFRA wild-type GISTs. Succinate dehydrogenase comprises four subunit proteins (SDHA, SDHB, SDHC, and SDHD) and two assembly factors (SDHAF1 and SDHAF2). SDHA and SDHB form the catalytic component of succinate-coenzyme Q reductase, whereas SDHC and SDHD comprise the anchoring component that attaches the complex to the inner mitochondrial membrane. These tumors are more commonly observed in children and young adults. Most gastric GIST patients under 18 years old and a significant percentage of patients under 30 years old fall into this category. While the exact cause of SDH deficiency in these tumors remains unclear, the association between SDH deficiency and SDH gene mutations is well-established. The primary function of SDH is to participate in the interface between the tricarboxylic acid cycle and the electron transport chain. It catalyzes the oxidation of succinate to fumarate. This complex plays a crucial role in regulating hypoxia-inducible factor 1α (HIF1α), which is a subunit of HIF1. HIF1 is a transcriptional activator of IGF2 and VEGF. SDH-deficient GISTs present clinical manifestations similar to other gastric tumors, including gastrointestinal bleeding and epigastric discomfort. Some patients diagnosed with SDH-deficient GISTs may exhibit symptoms associated with metastatic tumors in the abdomen or liver. The differential diagnosis for SDH-deficient GISTs is comparable to that of other gastrointestinal stromal tumors, which include carcinoma, perivascular epithelioid cell tumor, melanoma, epithelioid leiomyosarcoma, epithelioid angiosarcoma, glomus tumor, and even neuroendocrine tumors, especially when the tumor demonstrates epithelioid morphology. Traditional chemotherapy has limited efficacy in treating GISTs; however, the tyrosine kinase inhibitor imatinib has shown promising results in inhibiting their growth.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources &amp; assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: SDH-Deficient Gastrointestinal Stromal Tumor (GIST) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034